Literature DB >> 34355342

Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.

Mojtaba Malek1, Mohammad E Khamseh2, Haleh Chehrehgosha2, Sohrab Nobarani2, Fariba Alaei-Shahmiri3.   

Abstract

BACKGROUND: The triglyceride-glucose index (TyG), and TyG-driven parameters incorporating TyG and obesity indices have been proposed as reliable indicators of insulin resistance and its related comorbidities. This study evaluated the effectiveness of these indices in identifying hepatic steatosis in individuals with Type 2 diabetes (T2DM).
METHODS: This was a cross-sectional study consisting of 175 patients with T2DM (122 with and 53 without NAFLD). TyG index, triglyceride glucose-body mass index (TyG-BMI), triglyceride glucose-waist circumference (TyG-WC), and triglyceride glucose-waist-to-height ratio (TyG-WHtR) were determined using standard formulas. Controlled attenuation parameter (CAP) was measured by transient elastography (FibroScan).
RESULTS: Among obesity parameters, CAP showed the strongest correlation with WHtR, followed by BMI and WC (all P < 0.001). Regression analyses demonstrated TyG-WHtR as a significant predictor of NAFLD with the highest odds ratio, reaching 10.69 (95% CI: 1.68-68.22) for the top quartile (Q4) compared to the first quartile (P = 0.01), followed by TyG-BMI (Q4: 6.75; 95% CI: 1.49-30.67) and TyG-WC (Q4: 5.90; 95% CI: 0.99-35.18). Moreover, TyG-WHtR presented the largest AUC for detection of NAFLD (0.783, P < 0.001) in ROC analysis, followed by TyG-BMI (AUC: 0.751, P < 0.001), TyG-WC (AUC: 0.751, P < 0.001), and TyG (AUC: 0.647, P = 0.002). TyG-WHtR value of 5.58 (sensitivity: 79%, specificity: 68%, P < 0.001) was the best cut-off point to identify hepatic steatosis in this population.
CONCLUSIONS: This study confirmed that the TyG-related indices comprising TyG and obesity parameters can identify hepatic steatosis more successfully than TyG alone. Furthermore, our results highlighted TyG-WHtR as a simple and effective marker for screening fatty liver in patients with T2DM, which may be used practically in clinical setting.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diabetes mellitus; Hepatic steatosis; Non-alcoholic fatty liver disease; TyG; TyG-BMI; TyG-WC; TyG-WHtR

Year:  2021        PMID: 34355342     DOI: 10.1007/s12020-021-02815-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  48 in total

1.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.

Authors:  Raymond Kwok; Kai Chow Choi; Grace Lai-Hung Wong; Yuying Zhang; Henry Lik-Yuen Chan; Andrea On-Yan Luk; Sally She-Ting Shu; Anthony Wing-Hung Chan; Ming-Wai Yeung; Juliana Chung-Ngor Chan; Alice Pik-Shan Kong; Vincent Wai-Sun Wong
Journal:  Gut       Date:  2015-04-14       Impact factor: 23.059

2.  Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Roberto Tessari; Luciano Zenari; Giuseppe Lippi; Guido Arcaro
Journal:  Diabetes Care       Date:  2007-05-22       Impact factor: 19.112

3.  Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.

Authors:  Hossein Poustchi; Fariba Alaei-Shahmiri; Rokhsareh Aghili; Sohrab Nobarani; Mojtaba Malek; Mohammad E Khamseh
Journal:  Arch Iran Med       Date:  2021-03-01       Impact factor: 1.354

4.  Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Roberto Tessari; Luciano Zenari; Christopher Day; Guido Arcaro
Journal:  Diabetes Care       Date:  2007-02-02       Impact factor: 19.112

Review 5.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 6.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 7.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

8.  The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects.

Authors:  Luis E Simental-Mendía; Martha Rodríguez-Morán; Fernando Guerrero-Romero
Journal:  Metab Syndr Relat Disord       Date:  2008-12       Impact factor: 1.894

9.  The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.

Authors:  Shujun Zhang; Tingting Du; Jianhua Zhang; Huiming Lu; Xuan Lin; Junhui Xie; Yan Yang; Xuefeng Yu
Journal:  Lipids Health Dis       Date:  2017-01-19       Impact factor: 3.876

10.  Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: The Rural Chinese Cohort Study.

Authors:  Ming Zhang; Bingyuan Wang; Yu Liu; Xizhuo Sun; Xinping Luo; Chongjian Wang; Linlin Li; Lu Zhang; Yongcheng Ren; Yang Zhao; Junmei Zhou; Chengyi Han; Jingzhi Zhao; Dongsheng Hu
Journal:  Cardiovasc Diabetol       Date:  2017-03-01       Impact factor: 9.951

View more
  4 in total

1.  Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals.

Authors:  Azizullah Beran; Hazem Ayesh; Mohammed Mhanna; Waseem Wahood; Sami Ghazaleh; Ziad Abuhelwa; Wasef Sayeh; Nameer Aladamat; Rami Musallam; Reem Matar; Saif-Eddin Malhas; Ragheb Assaly
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

2.  Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.

Authors:  Jinwei Cai; Cuiting Lin; Shuiqing Lai; Yingshan Liu; Min Liang; Yingfen Qin; Xinghuan Liang; Aihua Tan; Yong Gao; Zheng Lu; Chunlei Wu; Shengzhu Huang; Xiaobo Yang; Haiying Zhang; Jian Kuang; Zengnan Mo
Journal:  Lipids Health Dis       Date:  2021-10-27       Impact factor: 3.876

3.  Impacts of Triglyceride Glucose-Waist to Height Ratio on Diabetes Incidence: A Secondary Analysis of A Population-Based Longitudinal Data.

Authors:  Wenting Xuan; Dixing Liu; Jiana Zhong; Huijin Luo; Xiuwei Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

4.  Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters.

Authors:  Yan Xue; Jiahui Xu; Man Li; Yueqiu Gao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.